Lymphangiomyomatosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Lymphangiomyomatosis}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {...") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Lymphangiomyomatosis}} | {{Lymphangiomyomatosis}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
==Overview== | |||
==Medical Therapy== | |||
The association of LAM with women of childbearing age suggests that hormonal stimulation plays a role in the disease process, and several approaches to treatment involve diminishing the effect of estrogen. At one time or another, therapeutic approaches have included | |||
*[[progesterone]] | |||
*[[oophorectomy]] | |||
*[[tamoxifen]] | |||
*[[gonadotropin-releasing hormone]] (GnRH) [[GnRH agonist|agonists]] | |||
*[[androgen]] therapy | |||
No therapy is clearly efficacious, and all have undesirable side-effects. There is some evidence which shows that tamoxifen may actually cause worsening of LAM in some patients.<ref>{{cite journal | title=Lymphangiomyomatosis: a report of three cases treated with tamoxifen | author=Clemm C, Jehn U, Wolf-Hornung B, Siemon G, and Walter G | journal=Klin Wochenschr | year=1987 | volume=65 | pages=391-393 | issue= }}</ref><ref>{{cite journal | title=Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways | author=Yu J, Astrinidis A, Howard S, and Henske E | journal=Am J Physiol Lung Cell Mol Physiol | year=2004 | volume=286 | pages=L694-L700 | issue= }}</ref> | |||
==References== | ==References== | ||
Revision as of 18:04, 14 September 2012
Template:Lymphangiomyomatosis Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Medical Therapy
The association of LAM with women of childbearing age suggests that hormonal stimulation plays a role in the disease process, and several approaches to treatment involve diminishing the effect of estrogen. At one time or another, therapeutic approaches have included
- progesterone
- oophorectomy
- tamoxifen
- gonadotropin-releasing hormone (GnRH) agonists
- androgen therapy
No therapy is clearly efficacious, and all have undesirable side-effects. There is some evidence which shows that tamoxifen may actually cause worsening of LAM in some patients.[1][2]
References
- ↑ Clemm C, Jehn U, Wolf-Hornung B, Siemon G, and Walter G (1987). "Lymphangiomyomatosis: a report of three cases treated with tamoxifen". Klin Wochenschr. 65: 391–393.
- ↑ Yu J, Astrinidis A, Howard S, and Henske E (2004). "Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways". Am J Physiol Lung Cell Mol Physiol. 286: L694–L700.